renal cell carcinoma (Cancer)

Search with Google Search with Bing
Information
Disease name
renal cell carcinoma
Disease ID
DOID:4450
Description
"A renal carcinoma that has_material_basis_in the lining of the proximal convoluted renal tubule of the kidney." [url:http\://en.wikipedia.org/wiki/Renal_cell_carcinoma, url:http\://www.cancer.gov/dictionary?CdrID=661352]
Disease area statistics
Chromosome band
Gene symbol Chromosome Start Stop The number of variant
VHL 3 10,141,778 10,153,667 2
CHEK2 22 28,687,763 28,741,838 2
PBRM1 3 52,547,990 52,679,713 2
FGFR3 4 1,793,293 1,808,867 2
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04438083 Active, not recruiting Phase 1 A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) June 16, 2020 April 2027
NCT05229601 Active, not recruiting Phase 1 A Study of HFB301001 in Adult Patients With Advanced Solid Tumors April 20, 2022 January 2025
NCT04416646 Active, not recruiting Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma February 27, 2019 March 1, 2024
NCT03141177 Active, not recruiting Phase 3 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma August 22, 2017 April 17, 2024
NCT04337970 Active, not recruiting Phase 1/Phase 2 Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer April 6, 2020 October 2024
NCT03624673 Active, not recruiting N/A Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell Carcinoma October 11, 2018 October 2025
NCT03501381 Active, not recruiting Phase 2 High Dose IL 2 and Entinostat in RCC May 24, 2018 April 2024
NCT02940639 Active, not recruiting Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy October 27, 2016 December 15, 2025
NCT03324373 Active, not recruiting Phase 1 Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) March 20, 2019 June 27, 2028
NCT04267120 Active, not recruiting Phase 2 Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) July 29, 2020 February 28, 2026
NCT04234113 Active, not recruiting Phase 1 Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors June 13, 2019 November 2024
NCT02009449 Active, not recruiting Phase 1 A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors November 15, 2013 August 25, 2024
NCT03634540 Active, not recruiting Phase 2 A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) September 27, 2018 August 31, 2025
NCT03173560 Active, not recruiting Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma August 17, 2017 March 31, 2024
NCT03108703 Active, not recruiting N/A Assessment of QoL and Outcomes With SBRT for RCC June 2015 December 2025
NCT04913337 Active, not recruiting Phase 1/Phase 2 Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies June 9, 2021 July 2025
NCT03829501 Active, not recruiting Phase 1/Phase 2 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer January 28, 2019 August 5, 2024
NCT02867592 Active, not recruiting Phase 2 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors May 18, 2017 September 21, 2024
NCT03502330 Active, not recruiting Phase 1 APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma June 9, 2018 October 2027
NCT04163289 Active, not recruiting Phase 1 Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation January 23, 2020 November 2028
NCT02811861 Active, not recruiting Phase 3 Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma October 13, 2016 July 31, 2024
NCT04152018 Active, not recruiting Phase 1 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. November 13, 2019 August 30, 2024
NCT03172754 Active, not recruiting Phase 1/Phase 2 Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma June 12, 2017 April 6, 2025
NCT05397093 Active, not recruiting Phase 1 ITIL-306 in Advanced Solid Tumors August 24, 2022 November 2039
NCT03170960 Active, not recruiting Phase 1/Phase 2 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors September 5, 2017 August 2024
NCT03228667 Active, not recruiting Phase 2 QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors December 11, 2018 December 2024
NCT03873402 Active, not recruiting Phase 3 A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer June 21, 2019 March 11, 2025
NCT05030506 Active, not recruiting Phase 1 A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) October 13, 2021 October 21, 2026
NCT02853331 Active, not recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) September 16, 2016 December 31, 2025
NCT03541902 Active, not recruiting Phase 2 Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma May 15, 2018 July 31, 2025
NCT02293980 Active, not recruiting Phase 1 A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) November 25, 2014 November 30, 2026
NCT02306954 Active, not recruiting Phase 2 Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer December 2014 December 2026
NCT04074967 Active, not recruiting Phase 1/Phase 2 Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab June 11, 2020 November 21, 2027
NCT03455452 Active, not recruiting Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer January 21, 2018 March 31, 2025
NCT03752398 Active, not recruiting Phase 1 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) May 1, 2019 September 2025
NCT03798626 Active, not recruiting Phase 1 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers May 22, 2019 December 30, 2024
NCT04040530 Active, not recruiting Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours June 7, 2019 February 7, 2026
NCT03552380 Active, not recruiting Phase 2 Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma August 31, 2018 August 2023
NCT04758507 Active, not recruiting Phase 1/Phase 2 Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma February 18, 2021 February 19, 2024
NCT05005195 Active, not recruiting N/A Yorkshire Kidney Screening Trial May 10, 2021 April 30, 2023
NCT02399124 Active, not recruiting N/A Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma July 2014 February 2026
NCT04022343 Active, not recruiting Phase 2 Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer August 6, 2019 May 25, 2025
NCT04704219 Active, not recruiting Phase 2 Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) February 23, 2021 October 22, 2025
NCT02432963 Active, not recruiting Phase 1 Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy June 14, 2016 December 31, 2024
NCT01224288 Active, not recruiting Phase 3 Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble January 5, 2011 April 30, 2025
NCT04005183 Active, not recruiting Renal Cell Carcinoma Microenvironment Discovery Project May 6, 2019 July 1, 2030
NCT03983954 Active, not recruiting Phase 1 Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors October 10, 2019 October 1, 2026
NCT02473536 Active, not recruiting Phase 1/Phase 2 Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC June 2015 January 2025
NCT03961698 Active, not recruiting Phase 2 Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma December 17, 2019 August 31, 2023
NCT02496208 Active, not recruiting Phase 1 Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors July 22, 2015 September 30, 2024
NCT03297593 Active, not recruiting Phase 2 Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma December 13, 2017 September 2026
NCT00918775 Active, not recruiting Follow-up After Metastasectomy in Patients With Kidney Cancer June 9, 2009 December 20, 2026
NCT04987203 Active, not recruiting Phase 3 Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma September 9, 2021 August 1, 2025
NCT03845166 Active, not recruiting Phase 1 A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors March 20, 2019 November 2024
NCT00715442 Active, not recruiting Phase 2 Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) June 24, 2008 June 30, 2025
NCT02568267 Active, not recruiting Phase 2 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) November 19, 2015 April 1, 2025
NCT03294083 Active, not recruiting Phase 1/Phase 2 A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma June 7, 2018 November 2023
NCT05863052 Active, not recruiting Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population January 31, 2022 July 2026
NCT02613819 Active, not recruiting Phase 2 Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney July 2016 April 2025
NCT03142334 Active, not recruiting Phase 3 Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) June 9, 2017 December 28, 2025
NCT03948724 Active, not recruiting N/A Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology December 11, 2019 February 2024
NCT05354102 Active, not recruiting Phase 1 A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 May 1, 2022 November 2025
NCT03937219 Active, not recruiting Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma June 25, 2019 March 2025
NCT04508725 Active, not recruiting N/A Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) December 5, 2020 December 2024
NCT04503148 Active, not recruiting N/A Anesthesia and Cancer Study: Renal Cell Carcinoma September 22, 2020 December 22, 2025
NCT05810571 Active, not recruiting N/A Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study March 1, 2023 April 3, 2024
NCT05311618 Active, not recruiting Phase 1 Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors May 11, 2022 June 2025
NCT04100694 Available Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
NCT00923845 Completed Phase 2 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer March 1, 2008 June 22, 2017
NCT00944905 Completed Phase 1 Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) July 2009 November 2012
NCT00970970 Completed Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease September 2009 November 2012
NCT00979381 Completed Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor October 2008 November 2009
NCT00980213 Completed Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland September 2009 December 2013
NCT01002937 Completed Novel Prognostic Markers in Renal Cancer December 1, 2008 December 17, 2014
NCT01014065 Completed A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) July 2011 January 2013
NCT01026337 Completed Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer April 2009 November 2018
NCT01034631 Completed Phase 1/Phase 2 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma January 2010 December 2016
NCT05168436 Completed A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal August 5, 2019 July 13, 2020
NCT01062178 Completed Phase 2 Efficacy of Ultrasound Contrast Agent to Assess Renal Masses October 2009 December 2012
NCT01100619 Completed Phase 1 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors April 2010
NCT01114230 Completed Phase 1 A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer August 2010 November 2012
NCT05070637 Completed N/A Circulating Tumor Cell Reducing No-touch Nephrectomy September 27, 2021 May 18, 2022
NCT01138124 Completed Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) March 2010 August 2010
NCT01173445 Completed Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma July 2010 May 2011
NCT05012865 Completed Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) September 14, 2021 January 31, 2022
NCT01176552 Completed Phase 2 Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer May 2004 May 2010
NCT01206764 Completed Phase 4 A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma. November 11, 2009 July 1, 2017
NCT01210482 Completed Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) August 2010 March 2018
NCT01227213 Completed The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma November 2010 November 2013
NCT01236053 Completed Cancer in Patients With Gabapentin (GPRD) June 2010 September 2010
NCT01254838 Completed Phase 1 Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma November 2008 December 2010
NCT01265810 Completed Phase 3 Caphosol in Oral Mucositis Due to Targeted Therapy November 2011 October 2015
NCT01272817 Completed N/A Nonmyeloablative Allogeneic Transplant October 2001 October 2015
NCT01283048 Completed Phase 1 Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma September 2011 September 2016
NCT01291420 Completed Phase 1/Phase 2 Dendritic Cell Vaccination for Patients With Solid Tumors May 3, 2010 May 5, 2018
NCT01297244 Completed Phase 2 A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma January 2011 October 2012
NCT01331135 Completed Phase 1 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors April 2011 August 9, 2017
NCT01339962 Completed Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. April 2011 April 2012
NCT01354431 Completed Phase 2 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) May 31, 2011 April 15, 2021
NCT01358721 Completed Phase 1 Phase I Biomarker Study (BMS-936558) September 23, 2011 May 22, 2019
NCT01361113 Completed Phase 2 Neoadjuvant Pazopanib in Renal Cell Carcinoma June 2011 February 15, 2017
NCT01391143 Completed Phase 1 Safety Study of MGA271 in Refractory Cancer July 2011 April 18, 2019
NCT04933604 Completed LPN in Patients With High-complex Renal Tumors September 1, 2019 February 4, 2021
NCT01399918 Completed Phase 2 Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) July 2011 December 28, 2020
NCT01404104 Completed N/A Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma September 2008 August 2014
NCT01405183 Completed Association Between Hepatitis C Infection and Renal Cell Carcinoma January 2011 September 2013
NCT01441661 Completed Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma November 2007 June 2012
NCT01442090 Completed Phase 2 Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy October 2011 July 2015
NCT04873180 Completed Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma January 1, 2020 December 30, 2020
NCT01472081 Completed Phase 1 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) February 9, 2012 June 3, 2021
NCT01482520 Completed Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma August 2008 October 2013
NCT04834778 Completed Phase 1 A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) June 8, 2021 January 30, 2024
NCT01497821 Completed Phase 1 AMG 172 First in Human Study in Patients With Kidney Cancer January 2012 January 2015
NCT01566747 Completed Phase 2 Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 March 2011 July 15, 2020
NCT04804813 Completed Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma March 29, 2021 March 31, 2024
NCT01585974 Completed Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma October 2012 November 2015
NCT04804163 Completed Early Phase 1 Research on the Effectiveness and Safety of Remote Control of Domestic Surgical Robot System for Urinary Surgery February 27, 2021 December 30, 2021
NCT01613846 Completed Phase 3 Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) May 2012
NCT01625351 Completed Phase 1 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas August 20, 2012 February 10, 2020
NCT01625936 Completed Phase 1 CRLX101 Plus Bevacizumab in Advanced RCC June 2012 July 16, 2018
NCT01665703 Completed N/A Imaging Correlates of Renal Cell Carcinoma Biological Features August 2012 January 2019
NCT04682587 Completed To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma February 24, 2021 April 5, 2021
NCT04637204 Completed Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England November 24, 2020 December 11, 2020
NCT04570176 Completed N/A Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System August 27, 2020 November 30, 2021
NCT01762150 Completed Phase 2 Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma June 2011 June 2018
NCT04540705 Completed Phase 1 A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread September 11, 2020 January 18, 2024
NCT04535687 Completed Phase 2 Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma December 17, 2020 June 12, 2023
NCT01773655 Completed Clinical and Histopathologic Characteristics of BAP1 Mutations January 2013 June 30, 2020
NCT01778933 Completed Early Phase 1 Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17) May 2013 September 2014
NCT04510688 Completed Spanish Real-World Evidence Cabozantinib October 23, 2019 June 30, 2022
NCT01798446 Completed Phase 2 A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus February 2013 December 2016
NCT04440943 Completed Phase 1 A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies August 4, 2020 April 6, 2023
NCT01836406 Completed N/A Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy December 2012 June 2013
NCT01865747 Completed Phase 3 A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma June 2013 January 15, 2021
NCT01887574 Completed N/A Renal Mass Registry June 2013 April 12, 2017
NCT04402749 Completed The Incidence of Pulmonary Embolism During Nephrectomy October 1, 2020 December 30, 2022
NCT04309617 Completed Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy July 31, 2019 April 28, 2020
NCT01975831 Completed Phase 1 A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab December 19, 2013 July 2, 2021
NCT01984242 Completed Phase 2 A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma January 8, 2014 January 8, 2019
NCT01997788 Completed N/A The Intrathecal Morphine for Nephrectomy August 2013 October 2013
NCT02030717 Completed Phase 2/Phase 3 Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma February 2012 May 2015
NCT02071862 Completed Phase 1 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors February 2014 March 2019
NCT04213157 Completed Laparoscopic Partial Nephrectomy for cT1 Tumors March 15, 2019 November 10, 2019
NCT02075658 Completed N/A A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation January 2003 September 2014
NCT02080650 Completed N/A Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) March 2014 July 19, 2016
NCT02082210 Completed Phase 1/Phase 2 A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer March 7, 2014 January 24, 2018
NCT02089685 Completed Phase 1/Phase 2 Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) March 17, 2014 April 1, 2021
NCT02133742 Completed Phase 1 A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer September 16, 2014 July 3, 2019
NCT02143492 Completed Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC August 2013 July 2015
NCT02160600 Completed N/A Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial April 2014 December 2016
NCT02162732 Completed N/A Molecular-Guided Therapy for Childhood Cancer July 8, 2014 January 18, 2024
NCT02216890 Completed Phase 1 Safety Study of SGN-CD70A in Cancer Patients August 2014 February 15, 2017
NCT02223052 Completed Phase 1 Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies October 27, 2014 December 18, 2018
NCT04077359 Completed N/A Prospective Trial for Examining Hematuria Using Computed Tomography September 15, 2019 July 1, 2021
NCT02264548 Completed Phase 1 A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy July 2009 August 4, 2020
NCT02315755 Completed Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC May 11, 2015 November 20, 2017
NCT02325921 Completed MRI in Renal Tumors October 2014 June 2018
NCT02326558 Completed N/A Comparison of Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma October 2014 September 2016
NCT02370290 Completed Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer April 2014 February 2016
NCT02386826 Completed Phase 1 INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme September 22, 2015 August 23, 2023
NCT02390843 Completed Phase 1 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors February 2015 September 22, 2019
NCT02420821 Completed Phase 3 A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) May 20, 2015 December 13, 2021
NCT02440334 Completed Phase 2 Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation April 23, 2015 June 21, 2018
NCT02498665 Completed Phase 1 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies November 2015 September 2018
NCT02526017 Completed Phase 1 Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers September 8, 2015 November 18, 2019
NCT02527304 Completed N/A Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery June 2015 May 2018
NCT02533258 Completed Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice December 2, 2015 May 12, 2016
NCT02537743 Completed Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma August 19, 2015 February 19, 2021
NCT02585362 Completed N/A Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program March 2016 October 2018
NCT02596035 Completed Phase 4 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma January 8, 2016 May 24, 2021
NCT02619253 Completed Phase 1 Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma February 23, 2016 March 28, 2023
NCT02645409 Completed N/A Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma December 29, 2015 April 2, 2019
NCT02677337 Completed N/A NCCN Renal Cell Registry March 2016 December 2016
NCT02687139 Completed N/A Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma October 2015 April 2019
NCT02718066 Completed Phase 1/Phase 2 Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer August 2016 September 2023
NCT03894618 Completed Phase 1 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas March 26, 2019 May 4, 2023
NCT02762006 Completed Phase 1 Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma December 20, 2016 November 6, 2020
NCT03427476 Completed Phase 1 CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma January 1, 2018 August 31, 2018
NCT03517488 Completed Phase 1 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors July 10, 2018 September 6, 2022
NCT03471897 Completed Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma April 28, 2016 January 18, 2018
NCT03494816 Completed Phase 2 Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion December 15, 2017 June 10, 2020
NCT03511391 Completed Phase 2 CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors March 9, 2018 January 23, 2024
NCT00056537 Completed Phase 1 ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer April 2003 December 2006
NCT00081614 Completed Phase 2 A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma March 2004 July 2005
NCT00087984 Completed Phase 1/Phase 2 RNA-Loaded Dendritic Cell Cancer Vaccine January 2004 September 2008
NCT00113217 Completed Phase 2 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma February 2005 August 2012
NCT06317207 Completed Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy January 1, 2013 December 31, 2023
NCT00199875 Completed Phase 1 Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 July 6, 2005 March 14, 2013
NCT00258687 Completed Phase 1 Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma January 2005 December 2020
NCT00272649 Completed Phase 1/Phase 2 Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer January 2006 February 2012
NCT00340457 Completed Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States November 16, 2001 January 1, 2016
NCT00353301 Completed Phase 2 Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma July 2006 March 2012
NCT00378482 Completed Phase 2 A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. March 5, 2007 October 27, 2023
NCT00384969 Completed Phase 1 Sorafenib and RAD001 Renal Cell Carcinoma October 2006 March 2014
NCT06055660 Completed Moesin Expression in Clear Cell Renal Cell Carcinoma January 1, 2017 December 31, 2021
NCT00420888 Completed Phase 2/Phase 3 ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma January 2007 January 2013
NCT00422344 Completed Phase 1 A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma October 2006 February 2010
NCT00423332 Completed Phase 2 Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma January 2007 October 2016
NCT00448721 Completed Phase 2 A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer March 2007 October 2011
NCT00460798 Completed SUTENT® In The First Line Treatment Of Renal Cell Carcinoma February 2007 September 2009
NCT00474786 Completed Phase 3 Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib September 2007 January 2013
NCT00478114 Completed Phase 3 Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) May 2007 March 2010
NCT00480389 Completed Phase 2 Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal May 2007 March 2013
NCT00490698 Completed Phase 2 Zoledronate With Atorvastatin in Renal Cell Carcinoma October 2006 January 2012
NCT00496587 Completed Phase 2 Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma July 2007 May 2016
NCT00513175 Completed Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia October 2001 November 2007
NCT00523159 Completed Phase 2 IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease May 2007 August 2009
NCT00550277 Completed Phase 2 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma January 2008 June 2010
NCT00556049 Completed Phase 2 Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma December 2007 December 2014
NCT00563147 Completed Phase 1 A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma November 2007 February 2011
NCT05800106 Completed Phase 1 A Bioequivalence Study of Sunitinib Malate Capsules. December 4, 2018 January 12, 2019
NCT00606632 Completed Phase 3 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody March 2008 December 2009
NCT00609401 Completed Phase 2 Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) November 2006 May 2008
NCT00609934 Completed Phase 1/Phase 2 Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone December 2007 October 2014
NCT00610012 Completed Tumor Registry of Advanced Renal Cell Carcinoma December 2007 May 15, 2020
NCT00617253 Completed Phase 2 Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients July 12, 2007 June 30, 2008
NCT00625456 Completed Phase 1 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors June 2008 June 2014
NCT00625755 Completed Phase 1/Phase 2 A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma December 2002 February 2008
NCT00631371 Completed Phase 3 Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects April 2008 April 2015
NCT00635791 Completed Phase 1 Phase I Study of Vorinostat and Sorafenib in Advanced Cancer March 2008 March 2012
NCT00678119 Completed Phase 2 Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment January 2008 May 2012
NCT05650164 Completed Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) January 25, 2023 October 13, 2023
NCT00717743 Completed T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY) March 2007
NCT00718367 Completed Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens March 2008 November 2013
NCT00729053 Completed Phase 2 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma June 2004 November 2008
NCT00730639 Completed Phase 1 A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies October 30, 2008 December 22, 2020
NCT00731211 Completed Phase 2 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma September 2008 September 2012
NCT00732914 Completed Phase 3 Sequential Study to Treat Renal Cell Carcinoma January 2009 December 2013
NCT00749320 Completed N/A Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) September 2008 December 2019
NCT00753415 Completed Phase 1 A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) August 2008 April 2011
NCT00782275 Completed Phase 2 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma April 2009 May 2015
NCT00788060 Completed Phase 1 A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma October 2008 December 2012
NCT00827359 Completed Phase 2 Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma March 2009 June 2018
NCT00830895 Completed Phase 2 RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC) January 2009 December 2012
NCT00831857 Completed VEGF Imaging in Renal Cell Carcinoma January 2009 September 2011
NCT00836745 Completed Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent March 2009 July 2012
NCT05375136 Completed A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients June 25, 2021 November 7, 2023
NCT05363072 Completed A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. June 1, 2022 September 30, 2022
NCT00876382 Completed Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma May 2009 August 2011
NCT00884520 Completed Early Phase 1 An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037 April 2009 March 2010
NCT00903175 Completed Phase 2 Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma October 2009 May 2015
NCT00918281 Completed Phase 2 Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection June 2009 October 2011
NCT00923130 Completed Phase 2 Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer January 7, 2009 June 2016
NCT00923169 Completed Phase 1 Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) July 9, 2006 January 20, 2010
NCT00923520 Completed Phase 1 A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies March 25, 2009 December 3, 2018
NCT03758781 Completed Phase 1 IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors February 13, 2019 August 11, 2021
NCT03029780 Completed Phase 2 An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma February 16, 2017 June 15, 2021
NCT03748901 Completed PD-L1 Expression in Japanese Renal Cell Carcinoma Patients December 16, 2018 July 21, 2021
NCT03744585 Completed Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts. November 6, 2018 July 7, 2019
NCT03052504 Completed Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy September 2016 February 2018
NCT03063762 Completed Phase 1 Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) March 20, 2017 June 14, 2021
NCT03699579 Completed Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC February 22, 2019 June 23, 2019
NCT03670992 Completed Surgical Treatment of Pancreatic RCC Metastases January 10, 2016 January 10, 2017
NCT03097328 Completed Phase 2 Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma August 1, 2017 April 24, 2024
NCT03161145 Completed A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread December 9, 2016 August 31, 2017
NCT03176485 Completed N/A Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors October 17, 2014 November 1, 2018
NCT03663946 Completed A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread September 18, 2018 May 30, 2020
NCT03652077 Completed Phase 1 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies September 24, 2018 August 18, 2021
NCT03190174 Completed Phase 1/Phase 2 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers August 24, 2017 December 2, 2021
NCT03200587 Completed Phase 1 Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) June 21, 2018 November 25, 2021
NCT03207347 Completed Phase 2 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) August 13, 2018 August 30, 2022
NCT03633110 Completed Phase 1/Phase 2 Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine August 29, 2018 February 28, 2022
NCT00001683 Completed Phase 1 A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer October 1997 August 2003
NCT00030992 Completed Phase 2 BMS 247550 to Treat Kidney Cancer February 2002 June 2012
NCT03319459 Completed Phase 1 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors January 18, 2018 December 15, 2020
NCT03629756 Completed Phase 1 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies July 24, 2018 September 3, 2021
NCT03329950 Completed Phase 1 A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies December 1, 2017 September 13, 2022
NCT03334344 Completed N/A Using Virtual Reality (VR) Models for Preoperative Planning October 24, 2017 March 18, 2019
NCT00033904 Completed Phase 3 Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer June 2000 April 2007
NCT00036036 Completed Phase 2 Study of CP-461 in Patients With Advanced Renal Cell Cancer July 2001 July 2003
NCT03419572 Completed Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma April 24, 2018 May 19, 2022
NCT02776644 Completed Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan October 15, 2016 December 30, 2017
NCT03849469 Completed Phase 1 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors May 29, 2019 February 16, 2023
NCT02809404 Completed Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) June 2015 January 2017
NCT02829775 Completed Phase 2/Phase 3 A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies January 2004 January 2008
NCT02835833 Completed Phase 1 Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors June 9, 2016 June 14, 2018
NCT02850809 Completed Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors October 2010 December 2015
NCT03841110 Completed Phase 1 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors February 15, 2019 November 15, 2022
NCT02853344 Completed Phase 2 Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) September 30, 2016 April 1, 2022
NCT02855203 Completed Phase 1/Phase 2 Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours October 20, 2016 May 22, 2020
NCT02883153 Completed Phase 2/Phase 3 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma December 2015 June 6, 2017
NCT03829436 Completed Phase 1 TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers March 20, 2019 September 7, 2022
NCT02923284 Completed NANOTECH RCC Biomarkers August 2016 January 2, 2020
NCT03776123 Completed Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients May 15, 2019 March 26, 2024
NCT03775850 Completed Phase 1 A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors December 19, 2018 October 31, 2021
NCT02982954 Completed Phase 4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer January 16, 2017 October 6, 2021
NCT02983045 Completed Phase 1/Phase 2 A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors December 19, 2016 April 28, 2022
NCT02989714 Completed Phase 1/Phase 2 Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer March 16, 2017 June 23, 2020
NCT00102544 Enrolling by invitation N/A Use of Tracking Devices to Locate Abnormalities During Invasive Procedures February 23, 2005 December 2, 2024
NCT04831138 Enrolling by invitation N/A Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma March 24, 2021 March 24, 2027
NCT03554434 No longer available An Expanded Access Program for AM0010 (Pegilodecakin)
NCT01473043 No longer available Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment March 2012 March 2014
NCT03874455 No longer available Tazemetostat Expanded Access Program for Adults With Solid Tumors
NCT04958473 Not yet recruiting Phase 2 A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer August 1, 2021 August 1, 2025
NCT06376669 Not yet recruiting Phase 2 Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma June 2024 August 2030
NCT05023265 Not yet recruiting N/A Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT October 2021 December 2026
NCT06444815 Not yet recruiting Phase 1 A Study of VET3-TGI in Patients With Solid Tumors August 1, 2024 December 31, 2027
NCT06049030 Not yet recruiting Phase 1 A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma September 25, 2023 September 25, 2025
NCT05124431 Not yet recruiting Phase 2 Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma December 2021 December 2024
NCT06093568 Not yet recruiting Delving Into Participation Trends in Renal Cell Carcinoma Studies November 2024 November 2026
NCT05149196 Not yet recruiting N/A Goal-directed Hemodynamic Management and Kidney Injury After Radical Nephrectomy June 30, 2024 December 30, 2034
NCT05798455 Not yet recruiting Phase 1/Phase 2 Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma May 22, 2023 May 22, 2026
NCT05808608 Not yet recruiting Phase 1/Phase 2 A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma September 2023 December 2025
NCT06453642 Not yet recruiting N/A Evaluation of a Simple-Prep Controlled Embolic June 2024 June 2026
NCT05843305 Not yet recruiting Phase 1 A Study of BPI-452080 in Subjects With Solid Tumors April 28, 2023 October 31, 2025
NCT05486871 Not yet recruiting N/A Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study. August 20, 2022 August 20, 2024
NCT06318871 Not yet recruiting Early Phase 1 Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma June 2024 February 28, 2030
NCT05941169 Not yet recruiting N/A Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy August 1, 2023 April 1, 2031
NCT05949424 Not yet recruiting Phase 4 OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults May 2024 March 2025
NCT06032728 Not yet recruiting N/A Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment October 1, 2023 October 1, 2033
NCT06383507 Not yet recruiting Phase 1 A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors April 22, 2024 April 21, 2029
NCT05725421 Not yet recruiting N/A Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy June 2024 July 2025
NCT06129955 Not yet recruiting Phase 2 Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma November 11, 2023 December 31, 2025
NCT06134700 Not yet recruiting N/A Low Pressure Versus Standard Pressure Pneumoperitoneum in Laparoscopic Nephrectomy November 15, 2023 December 15, 2024
NCT00001238 Recruiting Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders December 5, 1990
NCT00026663 Recruiting Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance August 9, 2000
NCT00898365 Recruiting Study of Kidney Tumors in Younger Patients February 27, 2006
NCT03212404 Recruiting Phase 1 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers September 20, 2017 December 2024
NCT03288532 Recruiting Phase 3 Renal Adjuvant MultiPle Arm Randomised Trial July 19, 2018 December 1, 2034
NCT03291028 Recruiting Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma November 27, 2017 December 2024
NCT03341845 Recruiting Phase 2 Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC March 28, 2018 January 31, 2025
NCT03374267 Recruiting Registry Platform Urologic Cancer December 7, 2017 June 2027
NCT03592472 Recruiting Phase 3 A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) July 17, 2018 June 30, 2025
NCT03630536 Recruiting TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative August 12, 2018 May 8, 2028
NCT03786796 Recruiting Phase 2 Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations June 3, 2019 March 2026
NCT03809624 Recruiting Phase 2 Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer January 30, 2019 December 2025
NCT03872947 Recruiting Phase 1 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors April 26, 2019 March 2025
NCT03981497 Recruiting Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms February 28, 2018 December 31, 2030
NCT04006522 Recruiting Phase 2 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma October 2, 2019 July 15, 2026
NCT04028479 Recruiting The Registry of Oncology Outcomes Associated With Testing and Treatment May 5, 2021 October 1, 2031
NCT04198766 Recruiting Phase 1 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) December 10, 2019 May 15, 2026
NCT04260802 Recruiting Phase 1/Phase 2 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers October 6, 2020 September 30, 2026
NCT04322955 Recruiting Phase 2 CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition June 22, 2020 February 2027
NCT04413123 Recruiting Phase 2 Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC November 5, 2020 December 20, 2025
NCT04495257 Recruiting Phase 1 A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) September 14, 2020 February 2025
NCT04495894 Recruiting Early Phase 1 Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma August 24, 2020 October 2024
NCT04510129 Recruiting A Multicenter Cancer Biospecimen Collection Study February 5, 2020 February 2027
NCT04601129 Recruiting Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery August 1, 2020 December 2023
NCT04623502 Recruiting N/A An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy September 30, 2019 September 30, 2026
NCT04631731 Recruiting Phase 1/Phase 2 Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity December 15, 2020 December 10, 2025
NCT04669860 Recruiting Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma February 24, 2021 January 1, 2026
NCT04707248 Recruiting Phase 1 A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors December 22, 2020 October 31, 2024
NCT04787042 Recruiting Phase 1/Phase 2 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 August 6, 2021 January 30, 2025
NCT04792463 Recruiting Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome March 3, 2015 July 1, 2026
NCT04883827 Recruiting Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer January 6, 2021 February 2026
NCT04892849 Recruiting Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy April 30, 2021 December 31, 2027
NCT04903873 Recruiting Phase 1/Phase 2 A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors May 31, 2021 December 2025
NCT04913025 Recruiting Phase 2 REduced Frequency ImmuNE Checkpoint Inhibition in Cancers May 26, 2022 April 2025
NCT04955743 Recruiting Phase 2 Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma February 9, 2022 March 31, 2028
NCT04960059 Recruiting NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts February 14, 2022 December 1, 2024
NCT04974671 Recruiting Phase 2 Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma August 8, 2022 April 1, 2027
NCT04977453 Recruiting Phase 1/Phase 2 GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors August 2, 2021 October 2026
NCT04981509 Recruiting Phase 2 Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer June 10, 2022 December 31, 2024
NCT04989959 Recruiting Phase 1 [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma August 18, 2021 August 18, 2026
NCT05013099 Recruiting Phase 2 Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies December 9, 2021 July 2025
NCT05024214 Recruiting Phase 1/Phase 2 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors November 15, 2021 June 2024
NCT05037825 Recruiting The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors November 22, 2021 September 14, 2028
NCT05048212 Recruiting Phase 2 A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases September 20, 2022 July 31, 2024
NCT05056077 Recruiting N/A Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) October 21, 2021 December 31, 2027
NCT05059444 Recruiting ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation September 7, 2021 February 2028
NCT05078047 Recruiting Phase 3 Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO March 8, 2022 March 7, 2025
NCT05098132 Recruiting Phase 1 Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors January 25, 2022 October 2025
NCT05119335 Recruiting Phase 1/Phase 2 A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma October 26, 2021 September 2026
NCT05148546 Recruiting Phase 2 Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer April 28, 2022 April 2029
NCT05176483 Recruiting Phase 1 Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors December 14, 2021 May 2026
NCT05180799 Recruiting Phase 1/Phase 2 A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors August 3, 2022 June 30, 2025
NCT05188118 Recruiting Early Phase 1 Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma February 24, 2023 December 2025
NCT05215574 Recruiting Phase 1 Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors March 31, 2022 March 2026
NCT05238883 Recruiting Phase 1 A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors March 10, 2022 December 2026
NCT05239143 Recruiting Phase 1 P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors February 15, 2022 April 2039
NCT05243173 Recruiting Biomarkers of Response to Systemic Treatments in FH-deficient RCC May 25, 2022 June 2024
NCT05256472 Recruiting Phase 2 A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma July 6, 2023 December 31, 2025
NCT05263245 Recruiting Phase 2 The Pharmacological Effects of Using Cabozantinib With a Light Breakfast May 25, 2023 May 2024
NCT05285579 Recruiting Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer May 5, 2022 August 2025
NCT05293496 Recruiting Phase 1 A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors April 19, 2022 March 2026
NCT05319015 Recruiting Phase 2 Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus January 6, 2023 August 2025
NCT05326620 Recruiting National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC) January 19, 2023 January 2030
NCT05420519 Recruiting Phase 1 Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer December 31, 2021 December 31, 2024
NCT05420545 Recruiting Phase 1 A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors December 31, 2021 December 31, 2024
NCT05429866 Recruiting Phase 2 Immunological Variables Associated to ICI Toxicity in Cancer Patients September 1, 2022 December 1, 2024
NCT05468190 Recruiting Phase 1 A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T July 17, 2022 July 17, 2025
NCT05468697 Recruiting Phase 1/Phase 2 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) August 10, 2022 March 16, 2027
NCT05501054 Recruiting Phase 1/Phase 2 Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. February 9, 2023 November 1, 2026
NCT05518253 Recruiting Phase 1 A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors May 30, 2022 May 30, 2025
NCT05534854 Recruiting Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes October 1, 2022 August 1, 2025
NCT05548621 Recruiting A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC) November 24, 2022 October 2024
NCT05592665 Recruiting N/A PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology March 18, 2022 January 7, 2031
NCT05621837 Recruiting Quantifying Systemic Immunosuppression to Personalize Cancer Therapy March 10, 2022 May 17, 2024
NCT05638256 Recruiting Early Phase 1 68Ga-labeled NY104 PET Imaging in Patients October 10, 2022 October 2023
NCT05641935 Recruiting Phase 2 Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation November 3, 2022 February 2028
NCT05653882 Recruiting Phase 1 A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors January 4, 2023 May 2027
NCT05661955 Recruiting Phase 1/Phase 2 A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. January 19, 2023 August 2025
NCT05700461 Recruiting Phase 1 Drug Screening Using Novel IMD in Renal Cell Carcinoma April 24, 2023 March 2026
NCT05703269 Recruiting N/A Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy July 11, 2023 March 31, 2028
NCT05705583 Recruiting A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma January 1, 2023 December 31, 2025
NCT05714553 Recruiting Phase 1/Phase 2 NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours March 8, 2023 January 2025
NCT05721222 Recruiting Phase 1/Phase 2 PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) March 15, 2023 April 30, 2025
NCT05733715 Recruiting Early Phase 1 Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma May 3, 2023 January 2028
NCT05738694 Recruiting Phase 2 Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma April 19, 2023 March 16, 2026
NCT05739812 Recruiting N/A The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery February 5, 2023 April 2024
NCT05744128 Recruiting Phase 2 CD8 Minibody Repeatability Study February 16, 2023 December 15, 2025
NCT05770037 Recruiting Phase 2/Phase 3 DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers December 18, 2023 October 2029
NCT05783622 Recruiting Phase 1 Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies April 19, 2023 October 2027
NCT05785052 Recruiting Biomarkers of Renal Cancer June 11, 2019 June 2026
NCT05788484 Recruiting Phase 1 A Study of CDX-585 in Patients With Advanced Malignancies May 11, 2023 February 2026
NCT05789069 Recruiting Phase 1 A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors May 9, 2023 December 2025
NCT05805501 Recruiting Phase 2 A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma April 21, 2023 March 31, 2026
NCT05830058 Recruiting Phase 2 Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma November 29, 2023 January 6, 2026
NCT05837767 Recruiting N/A A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue July 24, 2023 July 24, 2026
NCT05858736 Recruiting Phase 1 Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors July 11, 2023 June 15, 2025
NCT05867303 Recruiting Phase 1 A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors June 5, 2023 September 30, 2024
NCT05887245 Recruiting Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy April 17, 2023 January 1, 2030
NCT05902377 Recruiting Phase 2 68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma December 1, 2021 July 1, 2023
NCT05917106 Recruiting Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) December 26, 2022 June 2030
NCT05931393 Recruiting Phase 2 Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC) December 20, 2023 December 31, 2027
NCT05969496 Recruiting Phase 2 Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus December 4, 2023 November 2029
NCT06005818 Recruiting Phase 2 Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) December 1, 2023 June 30, 2025
NCT06010875 Recruiting Phase 1 A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors November 30, 2023 September 30, 2026
NCT06020651 Recruiting N/A Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside June 7, 2023 June 1, 2025
NCT06034860 Recruiting Phase 1 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types November 1, 2023 October 2026
NCT06047379 Recruiting Phase 1/Phase 2 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis November 1, 2023 August 31, 2026
NCT06053658 Recruiting Phase 2 Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma January 5, 2024 November 1, 2028
NCT06076538 Recruiting PET/MR for Characterization of Renal Masses (RMs) August 1, 2023 June 1, 2028
NCT06099782 Recruiting Phase 2 A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) December 26, 2023 November 16, 2026
NCT06101290 Recruiting N/A Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) October 5, 2023 January 5, 2031
NCT06182644 Recruiting N/A Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors January 11, 2024 September 1, 2025
NCT06182735 Recruiting Phase 1 CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma July 17, 2023 January 28, 2025
NCT06211790 Recruiting Phase 2 Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma January 16, 2024 December 30, 2026
NCT06234605 Recruiting Phase 1 A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma April 29, 2024 November 2027
NCT06255223 Recruiting Phase 2 A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy December 15, 2023 September 1, 2026
NCT06265025 Recruiting Phase 1/Phase 2 GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors February 20, 2024 October 30, 2028
NCT06265285 Recruiting Phase 2 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program March 13, 2024 December 31, 2026
NCT06285097 Recruiting Phase 1 A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors February 8, 2024 April 29, 2028
NCT06299163 Recruiting Phase 1 NM32-2668 in Adult Patients With Selected Advanced Solid Tumors May 1, 2024 December 31, 2027
NCT06307431 Recruiting Phase 2 A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) April 10, 2024 June 8, 2032
NCT06336187 Recruiting European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study) June 1, 2018 December 2030
NCT06342323 Recruiting The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy October 8, 2023 October 7, 2025
NCT06362369 Recruiting Phase 1/Phase 2 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy May 20, 2024 December 31, 2028
NCT06363123 Recruiting Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis March 29, 2024 April 2025
NCT06391879 Recruiting Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma September 8, 2023 August 31, 2025
NCT06424080 Recruiting N/A Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors. May 1, 2024 December 1, 2025
NCT06438588 Recruiting N/A Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial March 6, 2024 March 15, 2027
NCT00491075 Terminated Phase 2 Pemetrexed Plus Gemcitabine in Renal Cell Cancer December 2005 September 2011
NCT02795819 Terminated Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer July 8, 2016 March 14, 2019
NCT04596033 Terminated Phase 1 TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy November 11, 2020 June 27, 2022
NCT01144169 Terminated Phase 1 Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma October 2010 September 2016
NCT01762033 Terminated Phase 2 A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma February 2013 September 2015
NCT02747173 Terminated Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques October 2015 April 2018
NCT01720693 Terminated Phase 2 Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy June 2012 December 2014
NCT01466504 Terminated Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin May 2011 April 2013
NCT01771003 Terminated N/A Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy October 2012 September 2014
NCT02626754 Terminated Phase 2 A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population August 12, 2015 January 2, 2018
NCT02495103 Terminated Phase 1/Phase 2 Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma August 26, 2015 February 6, 2020
NCT00975806 Terminated Phase 1/Phase 2 Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma September 1, 2009 October 1, 2011
NCT00126178 Terminated Phase 3 Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer May 2005 March 2006
NCT00953446 Terminated N/A Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma June 15, 2010 September 13, 2011
NCT03435640 Terminated Phase 1/Phase 2 REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies March 15, 2018 May 9, 2022
NCT00485563 Terminated Phase 2 A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma June 2007 March 2009
NCT02410174 Terminated Phase 1 To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors May 2012 December 2016
NCT01063998 Terminated A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma September 2009 March 2012
NCT02338570 Terminated Phase 4 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) July 2015 February 2018
NCT04060342 Terminated Phase 1 GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma August 13, 2019 April 11, 2022
NCT01806064 Terminated Phase 1/Phase 2 Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma March 8, 2013 June 12, 2019
NCT01829971 Terminated Phase 1 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection April 2013 May 2017
NCT04088500 Terminated Phase 2 A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma September 3, 2020 November 15, 2021
NCT00672178 Terminated Phase 1/Phase 2 Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) March 2008 September 2009
NCT04106167 Terminated Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy June 11, 2019 August 11, 2023
NCT03387514 Terminated Phase 2 Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies December 8, 2018 June 29, 2021
NCT03576131 Terminated Phase 1/Phase 2 GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors April 30, 2018 October 12, 2021
NCT02138578 Terminated N/A Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma May 2014 February 2017
NCT02131376 Terminated N/A Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy May 9, 2014 August 29, 2019
NCT00323076 Terminated Phase 1/Phase 2 [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours September 12, 2006 February 4, 2019
NCT00480935 Terminated Phase 2 A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma October 2007 October 2011
NCT03621982 Terminated Phase 1 Study of ADCT-301 in Patients With Selected Advanced Solid Tumors November 9, 2018 December 14, 2022
NCT03343613 Terminated Phase 1 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors November 17, 2017 May 4, 2020
NCT02005614 Terminated N/A A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection November 2013 August 2018
NCT04629339 Terminated Phase 2 Study of INCB086550 in Select Solid Tumors September 2, 2021 March 26, 2024
NCT00100685 Terminated Phase 2 Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) January 2005 December 2007
NCT01115803 Terminated Phase 1 A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors March 2010 June 2011
NCT00684996 Terminated Phase 1/Phase 2 Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer June 2008 October 2010
NCT00001703 Terminated Phase 2 Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma August 1998 November 2008
NCT00934440 Terminated Phase 1/Phase 2 A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma June 2009 November 2015
NCT04271254 Terminated N/A PET/MR Characterization of Renal Cell Carcinomas October 1, 2020 June 14, 2023
NCT04301011 Terminated Phase 1/Phase 2 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors June 2, 2020 January 23, 2023
NCT01649180 Terminated Phase 2 NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma July 2012 March 2016
NCT04429321 Terminated Phase 1 Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary August 26, 2020 January 31, 2024
NCT03637803 Terminated Phase 1/Phase 2 Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors January 10, 2019 May 8, 2023
NCT04341740 Terminated N/A Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma July 22, 2020 April 9, 2021
NCT04628780 Terminated Phase 1 Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors December 16, 2020 May 26, 2023
NCT00561912 Terminated Phase 2 Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma October 2007 November 2009
NCT03655613 Terminated Phase 1/Phase 2 APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC September 5, 2018 December 15, 2021
NCT01441765 Terminated Phase 2 PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine November 2011 July 2016
NCT01392352 Terminated Phase 2 HYPAZ: Hypertension Induced by Pazopanib April 2011 September 2015
NCT00417677 Terminated Phase 1/Phase 2 A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma March 2007 May 2007
NCT01253668 Terminated Phase 2 Brivanib Metastatic Renal Cell Carcinoma November 2011 September 2013
NCT01598038 Terminated N/A Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma April 2012 December 2015
NCT00557830 Terminated Phase 2 Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma January 2008 April 2011
NCT00854022 Terminated Genetic Susceptibility to Kidney Cancer July 2008 March 2013
NCT03709771 Terminated Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease January 9, 2020 October 1, 2020
NCT03729245 Terminated Phase 3 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) December 18, 2018 October 19, 2022
NCT01677390 Terminated Phase 1 A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma August 2012 December 2013
NCT00330564 Terminated Phase 2 Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow May 2006 May 2011
NCT01582672 Terminated Phase 3 Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma November 2012 April 2018
NCT00491738 Terminated Phase 2 A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) August 2007
NCT03024996 Terminated Phase 3 A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy January 3, 2017 December 8, 2022
NCT02947152 Terminated Phase 1 HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma December 1, 2016 September 14, 2017
NCT00082459 Terminated Phase 2 Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma July 2002 December 2005
NCT00277316 Terminated Phase 2 Study of XL999 in Patients With Metastatic Renal Cell Carcinoma December 2005 June 2007
NCT01502228 Terminated N/A PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma October 2011 February 2014
NCT01482949 Terminated Phase 2 A Rollover Protocol for Subjects Previously Treated With AGS-003 September 2011 May 2018
NCT04691375 Terminated Phase 1 A Study of PY314 in Subjects With Advanced Solid Tumors October 29, 2020 September 22, 2023
NCT05769959 Terminated Phase 1/Phase 2 Study of RO7515629 in Participants With HLA-G Positive Solid Tumors June 15, 2023 March 19, 2024
NCT01147536 Terminated Phase 2 Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence January 2010 June 2012
NCT02853162 Terminated Phase 2 Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study) June 2016 April 2020
NCT01924156 Unknown status Phase 1/Phase 2 DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma July 2013 December 2016
NCT04798963 Unknown status N/A The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy March 2, 2021 March 2, 2022
NCT00006431 Unknown status Phase 1 Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA
NCT00869011 Unknown status Phase 3 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib December 2009
NCT00862303 Unknown status Phase 1/Phase 2 DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma March 2009 December 2015
NCT01240005 Unknown status Phase 1/Phase 2 Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma January 2011 September 2013
NCT04995016 Unknown status Phase 2 Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma August 20, 2021 August 20, 2023
NCT01216371 Unknown status Phase 2 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) October 2010 October 2015
NCT00777504 Unknown status Phase 4 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors October 2008 April 2012
NCT03464032 Unknown status Phase 1 A Study of BCD-135 in Patients With Advanced Solid Tumors October 31, 2017 October 31, 2018
NCT03393936 Unknown status Phase 1/Phase 2 Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma March 26, 2018 June 30, 2023
NCT03259477 Unknown status N/A RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCC February 1, 2018 October 2021
NCT03226886 Unknown status TRACERx Renal CAPTURE Sub-study February 5, 2012 September 1, 2023
NCT03177239 Unknown status Phase 2 Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) October 19, 2017 December 31, 2022
NCT03667885 Unknown status Non-Invasive Diagnostics of Small Renal Masses March 1, 2019 September 2020
NCT03094949 Unknown status N/A Comparison Between Partial Nephrectomy and Ablation for Renal Tumor July 1, 2008 September 1, 2017
NCT03685448 Unknown status Phase 2 ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) April 11, 2019 April 30, 2024
NCT03692533 Unknown status N/A Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma October 1, 2018 December 1, 2020
NCT03093688 Unknown status Phase 1/Phase 2 Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor March 1, 2017 June 30, 2023
NCT03738488 Unknown status N/A 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement December 1, 2019 May 30, 2022
NCT03050047 Unknown status Phase 1 A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors August 30, 2016 November 2018
NCT03047525 Unknown status Phase 1/Phase 2 Study of DC-CTL Combined With CIK for Advanced Solid Tumor February 20, 2017 December 1, 2020
NCT03033186 Unknown status Everolimus TDM to Predict Long Term Toxicity May 16, 2017 December 31, 2018
NCT02924597 Unknown status N/A Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage January 2016 August 2018
NCT00610389 Unknown status Phase 2 Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors February 2008 December 2010
NCT03827837 Unknown status Phase 2 Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors January 23, 2019 December 2022
NCT02919371 Unknown status Phase 1/Phase 2 Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) December 2014 December 2021
NCT02886897 Unknown status Phase 1/Phase 2 A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors July 2016 October 2019
NCT02849119 Unknown status N/A Transperitoneal vs Retroperitoneal Laparoscopic or Robotic Partial Nephrectomy January 2016 January 2017
NCT02787915 Unknown status Phase 1/Phase 2 DC1s-CTL Cellular Therapy for Renal Cell Carcinoma September 2016 August 2019
NCT03896958 Unknown status The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) March 21, 2019 March 12, 2024
NCT03928964 Unknown status MEtatastic Renal Carcinoma LINes January 15, 2018 April 2019
NCT02446860 Unknown status Phase 2 A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) April 2015 May 2018
NCT03987698 Unknown status Phase 2 Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma June 1, 2019 June 1, 2022
NCT02446795 Unknown status Phase 1/Phase 2 Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial November 2016 December 2017
NCT02208128 Unknown status N/A Molecular Determinants for Therapy Response on Renal Cell Carcinoma May 2014 February 2018
NCT04134182 Unknown status Phase 2 Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. October 16, 2019 December 2021
NCT04146831 Unknown status Phase 2 Sintilimab in FH-deficient Renal Cell Carcinoma June 1, 2020 April 1, 2023
NCT04177056 Unknown status N/A Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief December 4, 2020 January 1, 2023
NCT01041482 Unknown status Phase 2 A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma November 2008 November 2013
NCT02072044 Unknown status Phase 2 Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy December 2013 December 2017
NCT04213664 Unknown status Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma. December 31, 2019 January 31, 2020
NCT04244136 Unknown status Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries December 1, 2020 April 1, 2023
NCT05170555 Unknown status N/A Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 December 1, 2021 July 1, 2023
NCT02001493 Unknown status Metabolomic Profiling in Renal Cell Carcinoma January 2014 December 2015
NCT04268368 Unknown status Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors January 1, 2019 January 1, 2022
NCT01914263 Unknown status Phase 1 Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection March 2014 June 2016
NCT01892059 Unknown status N/A Study of Segmental Renal Artery Clamping During Laparoscopic Partial Nephrectomy May 2013 May 2016
NCT01890590 Unknown status N/A A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma July 2013 December 2023
NCT04424472 Unknown status N/A Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma July 17, 2020 December 1, 2022
NCT01838720 Unknown status N/A Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage April 2013 October 2014
NCT04534998 Unknown status Phase 2 Robotic-assisted vs. Open Partial Nephrectomy June 15, 2020 March 15, 2022
NCT04609293 Unknown status Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma October 20, 2020 May 7, 2024
NCT04666220 Unknown status VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma January 2, 2021 May 2021
NCT01711268 Unknown status Sunitinib Drug Levels and Outcomes in Kidney Cancer May 2012 December 2014
NCT02232646 Withdrawn Phase 2 A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies January 2017 August 1, 2018
NCT02307474 Withdrawn N/A A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer September 2015 September 2015
NCT01070186 Withdrawn Phase 2 Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma October 2010
NCT01781442 Withdrawn A Post Marketing Surveillance As Required By Philippine Food And Drug Administration June 2013 June 2015
NCT04688333 Withdrawn N/A iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma August 20, 2022 August 27, 2023
NCT02671552 Withdrawn Early Phase 1 Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery January 24, 2013 December 4, 2014
NCT01762592 Withdrawn Phase 3 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT December 2017 December 2019
NCT04555603 Withdrawn Axitinib Therapy Management Study September 15, 2020 February 22, 2021
NCT02763761 Withdrawn Phase 2 An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo August 16, 2016 March 31, 2017
NCT04580836 Withdrawn Phase 2 MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial August 19, 2020 November 17, 2021
NCT00601120 Withdrawn N/A RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma June 2007
NCT02928263 Withdrawn Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents February 28, 2017 May 31, 2017
NCT01176500 Withdrawn Phase 1/Phase 2 A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors July 28, 2010 November 18, 2011
NCT04609800 Withdrawn Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France. November 6, 2020 May 10, 2023
NCT03693573 Withdrawn Phase 3 A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma January 11, 2019 January 31, 2024
NCT03189186 Withdrawn Phase 1 Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas July 1, 2017 October 17, 2018
NCT03323710 Withdrawn Phase 2 Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma September 2018 December 2019
NCT03598816 Withdrawn Phase 2 PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma August 31, 2020 May 31, 2024
NCT00176280 Withdrawn Phase 2 Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma September 2005
NCT05418387 Withdrawn N/A A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona September 30, 2022 December 31, 2025
NCT00556205 Withdrawn Phase 2 Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma September 2009 September 2009
NCT00574483 Withdrawn Phase 2 Treatment of Advanced Renal Cell Carcinoma With Quinacrine November 2007 January 2008
NCT06090318 Withdrawn Phase 1/Phase 2 Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss May 19, 2023 May 30, 2023
NCT01834183 Withdrawn Phase 2 Tivozanib + Gemcitabine in Metastatic RCC June 2013 June 2013
NCT04262375 Withdrawn Phase 2 A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION January 2021 January 2024
NCT04260360 Withdrawn Phase 1 Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma April 2020 October 2022
Disase is a (Disease Ontology)
DOID:4451
Cross Reference ID (Disease Ontology)
EFO:0000681
Cross Reference ID (Disease Ontology)
GARD:13215
Cross Reference ID (Disease Ontology)
ICDO:8312/3
Cross Reference ID (Disease Ontology)
MESH:D002292
Cross Reference ID (Disease Ontology)
MIM:300854
Cross Reference ID (Disease Ontology)
NCI:C9385
Cross Reference ID (Disease Ontology)
ORDO:217071
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:254915003
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0007134
Exact Synonym (Disease Ontology)
adenocarcinoma of kidney
Exact Synonym (Disease Ontology)
hypernephroma
Exact Synonym (Disease Ontology)
RCC
HPO alt_id (Human Phenotype Ontology)
HP:0006720
HPO Human Phenotype ID (Human Phenotype Ontology)
HP:0005584